Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G

Biomedicine and Pharmacotherapy

Volumn 59, Issue 8, 2005, Pages 430-437

  Catalone, Bradley J ^a,e   Miller, Shendra R ^b   Ferguson, Mary Lee ^b   Malamud, Dan ^c   Kish Catalone, Tina ^b   Thakkar, Nina J ^b   Krebs, Fred C ^b   Howett, Mary K ^d   Wigdahl, Brian ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DREXEL UNIVERSITY   (United States)

^e Olympus America Inc   (United States)

Author keywords

Amine oxide; Betaine; C31G; HIV 1; Microbicide; Surfactant; Swiss Webster mouse model

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETAINE DERIVATIVE; C 14 AO; C 16 B; C 31 G; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DISEASE MODEL; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; UTERINE CERVICITIS; UTERINE CERVIX; VAGINA;

ADMINISTRATION, INTRAVAGINAL; AMINES; ANIMALS; ANTI-HIV AGENTS; BETAINE; CELL LINE; CELL SURVIVAL; CERVIX UTERI; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; FEMALE; HIV-1; HUMANS; INFLAMMATION; MICE; MODELS, ANIMAL; MUCOUS MEMBRANE;

EID: 25644452139     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2005.07.008     Document Type: Article

References (24)

1. R.C. Aloia, F.C. Jensen, C.C. Curtain, P.W. Mobley, and L.M. Gordon Lipid composition and fluidity of the human immunodeficiency virus Proc. Natl. Acad. Sci. USA 85 1988 900 904
2. R. Bax, K. Douville, D. McCormick, M. Rosenberg, J. Higgins, and M. Bowden Microbicides - evaluating multiple formulations of C31G Contraception 66 2002 365 368
3. S. Calis, N. Yulug, M. Sumnu, A. Ayhan, and A.A. Hincal A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures Boll. Chim. Farm. 131 1992 335 338
4. B.J. Catalone, M.L. Ferguson, S.R. Miller, D. Malamud, T. Kish-Catalone, and N. Thakkar Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure 2005 Biomed Pharmacother (in this issue)
5. B.J. Catalone, T.M. Kish-Catalone, L.R. Budgeon, E.B. Neely, M. Ferguson, and F.C. Krebs Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides Antimicrob. Agents Chemother. 48 2004 1837 1847
6. B.J. Catalone, T.M. Kish-Catalone, E.B. Neely, L.R. Budgeon, M.L. Ferguson, and C. Stiller Comparative safety evaluation of the candidate vaginal microbicide C31G Antimicrob. Agents Chemother. 49 2005 1509 1520
7. B.J. Catalone, F.C. Krebs, M. Labib, and B. Wigdahl Broad-spectrum microbicides as a strategy for reducing sexually transmitted disease prevalence and HIV-1 transmission Res. Adv. in Antimicrob. Agents Chemother 2 2001 55 80
8. P. Charneau, G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel HIV-1 reverse transcription. A termination step at the center of the genome J. Mol. Biol. 241 1994 651 662
9. A.M. Corner, M.M. Dolan, S.L. Yankell, and D. Malamud C31G, a new agent for oral use with potent antimicrobial and antiadherence properties Antimicrob. Agents Chemother. 32 1988 350 353
10. R.N. Fichorova, and D.J. Anderson Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells Biol. Reprod. 60 1999 508 514
11. R.N. Fichorova, J.G. Rheinwald, and D.J. Anderson Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins Biol. Reprod. 57 1997 847 855
12. R.N. Fichorova, L.D. Tucker, and D.J. Anderson The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission J. Infect. Dis. 184 2001 418 428
13. Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) AIDS epidemic update - December 2004. Geneva, Switzerland 2004
14. F.C. Krebs, S.R. Miller, B.J. Catalone, R. Fichorova, D. Anderson, and D. Malamud Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate Antimicrob. Agents Chemother. 46 2002 2292 2298
15. F.C. Krebs, S.R. Miller, B.J. Catalone, P.A. Welsh, D. Malamud, and M.K. Howett Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes Antimicrob. Agents Chemother. 44 2000 1954 1960
16. F.C. Krebs, S.R. Miller, D. Malamud, M.K. Howett, and B. Wigdahl Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate Antiviral Res. 43 1999 157 173
17. C.K. Mauck, M.D. Creinin, K.T. Barnhart, S.A. Ballagh, D.F. Archer, and M.M. Callahan A phase I comparative postcoital testing study of three concentrations of C31G Contraception 70 2004 227 231
18. C.K. Mauck, R.G. Frezieres, T.L. Walsh, S.W. Schmitz, M.M. Callahan, and R. Bax Male tolerance study of 1% C31G Contraception 70 2004 221 225
19. C.K. Mauck, D.H. Weiner, M.D. Creinin, K.T. Barnhart, M.M. Callahan, and R. Bax A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength gynol II Contraception 70 2004 233 240
20. E.B. Michaels, E.C. Hahn, and A.J. Kenyon Effect of C31G, an antimicrobial surfactant, on healing of incised guinea pig wounds Am. J. Vet. Res. 44 1983 1378 1381
21. R.J. Shattock, and J.P. Moore Inhibiting sexual transmission of HIV-1 infection Nat. Rev. Microbiol. 1 2003 25 34
22. K.A. Thompson, D. Malamud, and B.T. Storey Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9 Contraception 53 1996 313 318
23. J.A. Turpin Considerations and development of topical microbicides to inhibit the sexual transmission of HIV Expert Opin. Investig. Drugs 11 2002 1077 1097
24. P.B. Wyrick, S.T. Knight, D.G. Gerbig Jr., J.E. Raulston, C.H. Davis, and T.R. Paul The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro Antimicrob. Agents Chemother. 41 1997 1335 1344